Spyre Therapeutics files $500M mixed securities shelf

From time to time, the company may issue, in one or more series or classes, up to $500M in aggregate principal amount of its common stock, preferred stock, debt securities, warrants and/or units, at prices and on terms that it will determine at the time of the offering.